Literature DB >> 5004110

Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70.

M S Artenstein, H Schneider, M D Tingley.   

Abstract

Examination of large numbers of strains of meningococci associated with systemic disease in US Army personnel over a 7-year period has shown a changing pattern of sero-group prevalence and an increasing proportion of sulfadiazine-resistant organisms. These findings underline the failure of sulfadiazine prophylaxis and the necessity of applying a specific vaccine to this population. Knowledge of this kind from other populations will be required in order to provide appropriate control measures-vaccine or chemoprophylaxis.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5004110      PMCID: PMC2427927     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  12 in total

1.  Acute respiratory disease and meningococcal infection in army recruits.

Authors:  M S Artenstein; J H Rust; D H Hunter; T H Lamson; E L Buescher
Journal:  JAMA       Date:  1967-09-25       Impact factor: 56.272

2.  Prevalence of meningococcal serogroups and description of three new groups.

Authors:  J R Evans; M S Artenstein; D H Hunter
Journal:  Am J Epidemiol       Date:  1968-05       Impact factor: 4.897

3.  Sulphadiazine-resistant group A meningococci isolated during the 1968 meningitis epidemic in Greece.

Authors:  P Vassiliadis; A Kanellakis; J Papadakis
Journal:  J Hyg (Lond)       Date:  1969-06

4.  Trends in meningococcal disease.

Authors:  J V Bennet; L S Young
Journal:  J Infect Dis       Date:  1969-11       Impact factor: 5.226

5.  Prevention of meningococcal infections.

Authors:  E Sanders; W B Deal
Journal:  J Infect Dis       Date:  1970-04       Impact factor: 5.226

6.  [Sensitivity of meningococci of serotype A to sulfonamide drugs].

Authors:  M Vandekerkove; G Causse; L Lapeyssonnie; R Faucon
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

7.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

8.  Sulfadiazine-resistant group A Neisseria meningitidis.

Authors:  C E Alexander; W R Sanborn; G Cherriere; W H Crocker; P E Ewald; C R Kay
Journal:  Science       Date:  1968-09-06       Impact factor: 47.728

9.  Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  9 in total

1.  Comparative study of group A and group C meningococcal infection.

Authors:  L G Evans-Jones; H C Whittle; I I Onyewotu; L J Egler; B M Greenwood
Journal:  Arch Dis Child       Date:  1977-04       Impact factor: 3.791

2.  Incidence of haemagglutinating antibodies to meningococci in north-west England.

Authors:  D M Jones; B M Tobin
Journal:  J Clin Pathol       Date:  1972-11       Impact factor: 3.411

3.  Editorial: Vaccination against meningitis.

Authors: 
Journal:  Br Med J       Date:  1976-04-17

Review 4.  Meningococcal glycoconjugate vaccines.

Authors:  Roberto Gasparini; Donatella Panatto
Journal:  Hum Vaccin       Date:  2011-02-01

5.  Meningococcal carrier rates in parts of eastern Nigeria.

Authors:  A N Njoku-Obi; J A Agbo
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

6.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

7.  Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy.

Authors:  J B McCormick; H H Gusmão; S Nakamura; J B Freire; J Veras; G Gorman; J C Feeley; P Wingo
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

8.  Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis.

Authors:  J J Kim; R E Mandrell; Z Hu; M A Westerink; J T Poolman; J M Griffiss
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

9.  Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.

Authors:  Manisha Patel; Sandra Romero-Steiner; Michael P Broderick; Cynthia G Thomas; Brian D Plikaytis; Daniel S Schmidt; Scott E Johnson; Andrea S Milton; George M Carlone; Thomas A Clark; Nancy E Messonnier; Amanda C Cohn; Dennis J Faix
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.